Title of article
The RAF Inhibitor Paradox Revisited
Author/Authors
Cox، نويسنده , , Adrienne D. and Der، نويسنده , , Channing J.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2012
Pages
3
From page
147
To page
149
Abstract
The success of the RAF protein kinase inhibitor vemurafenib for the treatment of BRAF mutant metastatic melanoma has produced another poster child for the promise of personalized medicine. However, the results of a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies.
Journal title
Cancer Cell
Serial Year
2012
Journal title
Cancer Cell
Record number
1337791
Link To Document